Skip to main content
. 2023 Feb 14;12(4):612. doi: 10.3390/cells12040612

Figure 7.

Figure 7

Co-administration of Lenvatinib with Curcumin diminished the spheroid-forming ability via suppression of cancer stemness markers. (A) Representative images of cancer spheroids from Lenvatinib-resistant cells following treatment (magnification 100×). Scale bar = 500 μM. (B) Number and size of spheroids following treatment (*: p < 0.05 vs. control, #: p < 0.05 vs. Lenvatinib, %: p < 0.05 vs. Curcumin). (C) Gene expression changes in CD44 and CD133 genes (*: p < 0.05 vs. control, #: p < 0.05 vs. Lenvatinib, %: p < 0.05 vs. Curcumin). (D) A schematic illustration of the Curcumin and Lenvatinib combination treatment overcoming Lenvatinib resistance via suppression of EGFR and its downstream signaling. The data indicate mean (column) ± SD values. SD, standard deviation.